214 results on '"Holtrich, U."'
Search Results
2. Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
3. THE PROGNOSTIC IMPACT OF SPHINGOSINE-KINASE 1 EXPRESSION (SPHK1) ON OVARIAN CANCER: EP833
4. Prognostic impact of thymidine phosphorylase expression in breast cancer – Comparison of microarray and immunohistochemical data
5. Clinical relevance of the putative stem cell marker p63 in breast cancer
6. Das Stammzellkonzept der Mamma
7. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
8. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial
9. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
10. 127O Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
11. Clinical relevance of the putative stem cell marker p63 in breast cancer: PO238
12. The Luminal B marker NHERF1 predicts endocrine resistance: PO058
13. Die prognostische Bedeutung der Thymidinphosphorylase beim Mammakarzinom: PO038
14. EP833 The prognostic impact of sphingosine-kinase 1 expression (SphK1) on ovarian cancer
15. Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling
16. Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene
17. Therapiespezifische Besonderheiten und Prognose von metastasierten Mammakarzinompatientinnen, die zwischen 2010 und 2015 an einer Universitätsfrauenklinik behandelt wurden
18. Expression of Sphingosine-Kinase 1 (SPHK1) as a prognostic factor in ovarian cancer
19. Abstract P2-09-02: Blinded molecular subtyping analysis from RNA-Seq of FFPE samples in the GeparQuinto trial reveals predictive value of VEGFA metagene for bevacizumab treatment
20. Immune pruning of genomic heterogeneity in TNBC
21. 9O - Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling
22. The expression of PLK, a human serine/threonine kinase, is linked to the proliferative activity of cells and correlates with the prognosis of lung tumor patients
23. Abstract S1-07: Immune sculpting of the triple negative breast cancer genome
24. Expression and impact of TFF3 in epithelial ovarian cancer
25. Genexpressionsprofile von Mammakarzinomen vor einer primär systemischen Chemotherapie: Konkordanz mit Routinemarkern und Identifikation prädiktiver Signaturen
26. ER-β Promotrmethylierung korreliert mit der Entstehung des invasiven Mammakarzinoms
27. Immunhistochemische Expressionsanalyse von Östrogenrezeptor α (ER-α), Progesteronrezeptor (PR), Her-2/neu und Kit des Ductalen carcinoma in situ (DCIS): Co-Expression von Her-2/neu und Kit
28. Das Mammastammzellkonzept – ein theoretisches Konstrukt oder klinisch bedeutsam?
29. Molecular markers as prognostic factors in DCIS and small invasive breast cancers
30. 40P - Immune pruning of genomic heterogeneity in TNBC
31. c-kit: identification of co-regulated genes in breast cancer patients by gene expression analysis and discrimination of two breast cancer subtypes with stem-cell-like features
32. Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers
33. OPG and PGR Show Similar Cohort Specific Effects as Prognostic Factors in ER Positive Breast Cancer
34. Abstract P4-04-06: Systematic analysis of molecular subgroups and age in patients with breast cancer
35. Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer
36. Abstract P2-10-17: SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study.
37. 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set)
38. P2-12-11: Clinical Relevance of a IL-8/B-Cell Gene Signature Identified from Triple Negative Breast Cancer (TNBC) in Intrinsic Breast Cancer Subtypes.
39. P3-01-12: Prognostic Impact of RANK, RANKL and OPG Gene Expression in ER Positive Primary Breast Cancer.
40. PD03-02: Prognostic and Predictive Predictors for Triple Negative Breast Cancer.
41. Die prognostische und prädiktive Bedeutung der Sphingolipide beim primären Mammakarzinom
42. Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer.
43. Correlation of acid ceramidase (AC), a key enzyme of the sphingolipid metabolism, with prognosis in epithelial ovarian cancer.
44. Assoziation von CT-X Antigen Expression mit schlechter Prognose bei triple-negativem Mammakarzinom
45. Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer
46. Prognostische Bedeutung der Glucosylceramidsynthase beim Mammakarzinom
47. Tandem mass technology: A helpful tool for proteomic research in breast cancer?
48. Clinically relevant gene signatures in triple-negative and basal-like breast cancer.
49. Prognostic relationship of SATB1 gene expression and estrogen receptor status in breast cancer cells.
50. Methodischer Bias retrospektiver Follow-up-Untersuchungen und sein Einfluss auf die Erhebung von Qualitätssicherungsdaten
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.